Use of an electronic nose to diagnose Mycobacterium bovis infection in badgers and cattle.
(49/548)
It is estimated that more than 50 million cattle are infected with Mycobacterium bovis worldwide, resulting in severe economic losses. Current diagnosis of tuberculosis (TB) in cattle relies on tuberculin skin testing, and when combined with the slaughter of test-positive animals, it has significantly reduced the incidence of bovine TB. The failure to eradicate bovine TB in Great Britain has been attributed in part to a reservoir of the infection in badgers (Meles meles). Accurate and reliable diagnosis of infection is the cornerstone of TB control. Bacteriological diagnosis has these characteristics, but only with samples collected postmortem. Unlike significant wild animal reservoirs of M. bovis that are considered pests in other countries, such as the brushtail possum (Trichosurus vulpecula) in New Zealand, the badger and its sett are protected under United Kingdom legislation (The Protection of Badgers Act 1992). Therefore, an accurate in vitro test for badgers is needed urgently to determine the extent of the reservoir of infection cheaply and without destroying badgers. For cattle, a rapid on-farm test to complement the existing tests (the skin test and gamma interferon assay) would be highly desirable. To this end, we have investigated the potential of an electronic nose (EN) to diagnose infection of cattle or badgers with M. bovis, using a serum sample. Samples were obtained from both experimentally infected badgers and cattle, as well as naturally infected badgers. Without exception, the EN was able to discriminate infected animals from controls as early as 3 weeks after infection with M. bovis, the earliest time point examined postchallenge. The EN approach described here is a straightforward alternative to conventional methods of TB diagnosis, and it offers considerable potential as a sensitive, rapid, and cost-effective means of diagnosing M. bovis infection in cattle and badgers. (+info)
env Gene typing of human immunodeficiency virus type 1 strains on electronic microarrays.
(50/548)
The NanoChip system was used for subtyping human immunodeficiency virus type 1 (HIV-1) strains using probes complementary to the V1 region of the env gene. Probes for six subtypes (A to D, F, and G) and two circulating recombinant forms (AG and AE) of HIV-1 group M were included. The specificity of these oligonucleotides had been evaluated previously in a DNA enzyme immunoassay. Samples from 112 patient sera were used as templates in a nested reverse transcription-PCR to produce amplicons that were applied to the array. The array was then hybridized successively to pairs of oligonucleotide probes. The strains were assigned a subtype on the basis of their probe hybridization patterns. One strain gave a contradictory pattern and was designated as untypeable by the NanoChip assay. Eighty-eight strains gave hybridization patterns that allowed a correct subtype designation to be made by the NanoChip assay compared to either the sequence or the heteroduplex mobility assay (HMA)-determined subtypes. Thirteen strains that reacted with the subtype A probe (SA2) were incorrectly assigned to subtype A, or to one of the related circulating recombinant types (AE or AG), on the basis of reactions with probe SAE1 or SAG1. The results indicate that these oligonucleotides have relatively low specificities. The probe subtypes of three strains matched the subtypes determined for the gag and pol genes but not the env gene, suggesting that a recombination event may have occurred within the env gene. Overall, the NanoChip assay gave results comparable to those for HMA and sequencing and provides a convenient and cost-effective means by which to subtype HIV-1. (+info)
Cancer incidence among workers potentially exposed to chlorinated solvents in an electronics factory.
(51/548)
A retrospective cohort morbidity study based on standardized incidence ratios (SIRs) was conducted to investigate the possible association between exposure to chlorinated organic solvents and various types of cancers in an electronics factory. The cohort of the exposed group was retrieved from the Bureau of Labor Insurance (BLI) computer database records dating from 1978 through December 31, 1997. Person-year accumulation began on the date of entry to the cohort, or January 1, 1979 (whichever came later), and ended on the closing date of the study (December 31, 1997), if alive without contracting any type of cancers, or the date of death, or the date of the cancer diagnosis. Vital status and cases of cancer of study subjects were determined from January 1, 1979 to December 31, 1997 by linking cohort data with the National Cancer Registry Database. The cancer incidence of the general population was used for comparison. After adjustment for age and calendar year, only SIR for breast cancer in the exposed female employees were significantly elevated when compared with the Taiwanese general population, based on the entire cohort without exclusion. The SIR of female breast cancer also showed a significant trend of period effect, but no significant dose-response relationship on duration of employment. Although the total cancer as well as the cancer for trachea, bronchus and lung for the entire female cohort was not significantly elevated, trend analysis by calendar-year interval suggested an upward trend. However, when duration of employment or latency was taken into consideration, no significantly elevated SIR was found for any type of cancer in either male or female exposed workers. In particular, the risk of female breast cancer was not indicated to be increased. No significant dose-response relationship on duration of employment and secular trend was found for the above-mentioned cancers. This study provides no evidence that exposure to chlorinated organic solvents at the electronics factory was associated with elevated human cancers. Dominant short-term employees may bias the cancer risk toward false positive. (+info)
Cost evaluation of the use of conventional and electronic identification and registration systems for the national sheep and goat populations in Spain.
(52/548)
A cost model was developed to compare different implementation strategies of the new European Commission regulation for sheep and goat identification and registration (EC 21/2004) in Spain. Strategies were as follows: 1) conventional identification (CID) by two ear tags; 2) electronic identification (EID) by one bolus and one ear tag; and 3) mixed CID and EID strategy (MID), consisting of CID for fattening stock and EID for breeding stock. Complete and simplified implementations of the regulation were considered as options. Total costs per animal identified for all strategies and options varied according to the implementation option, ranging from Euros 2.48 and 4.64. The EID was the most expensive strategy (Euros 4.47 to 4.64) for all implementation options. Cost of CID and MID strategies ranged from Euros 2.63 to 2.98 and from Euros 2.48 to 3.03, respectively. The model was submitted to a sensitivity analysis without considering extra benefits of sheep and goat identification. Critical values for which the cost of MID equaled CID depended on strategy and option, and ranged from 7.5 to 11.5% for ear tag losses and from Euros 1.80 to 3.30 for bolus price. In conclusion, the use of a mixed strategy combining conventional ear tags (animals intended for slaughter) and electronic boluses (breeding stock) seems to be an affordable strategy that fulfills the European Commission regulation requirements for the identification of sheep and goats in Spain. Price reductions for devices and equipment would make the full electronic identification strategy less expensive in the future. (+info)
Twelve-month drug cost savings related to use of an electronic prescribing system with integrated decision support in primary care.
(53/548)
OBJECTIVE: We reported previously the results of a 6-month controlled trial in which the use of a commercially available electronic prescribing system with integrated clinical decision support and evidence-based message capability was associated with significantly lower primary care drug costs. The original study focused on new prescriptions, defined as claims for a medication that the patient had not received in the previous 12 months. The main objectives of this follow-up report were to (a) determine if the 6-month savings on new prescriptions were sustained during 12 months of follow-up, (b) evaluate the impact of the computerized decision support system (CDSS) on all pharmacy claims and per-member-per-month (PMPM) expenditures, and (c) evaluate the prescribing behaviors within 8 high-cost therapeutic categories that were frequently targeted by the electronic messages to prescribers to help verify that the drug cost savings were due to the recommendations in the electronic prescribing system. METHODS: Two database queries were performed to identify additional pharmacy claims data for all Network Health Plan patients who were cared for by the 38 primary care clinicians (32 physicians, 4 nurse practitioners, and 2 physician assistants) included in our original 6-month study. This follow-up analysis (a) identified all new prescription claims for the 2 groups of clinicians throughout the 12-month follow-up period (June 2002 through May 2003) and (b) assessed all pharmacy claims during the same 12-month period to provide more complete savings estimates and to examine between-group differences in PMPM expenditures. RESULTS: During 12 months of follow-up, clinicians using the electronic prescribing system continued to have lower prescription costs than the controls. Clinicians using the electronic prescribing system had average costs for 26,674 new prescriptions that were dollar 4.12 lower (95% confidence interval, dollar 1.53-dollar 6.71; P=0.003) and PMPM expenditures that were dollar 0.57 lower than expected based on the changes observed for 24,507 new prescriptions written by clinicians in the control group. The average drug cost savings on new prescriptions were dollar 482 per prescriber per month (PPPM), based upon prescription cost and dollar 465 PPPM based upon PMPM analysis. When all pharmacy claims (156,429) were analyzed, the intervention group.s average prescription cost was dollar 2.57 lower and their PMPM expenditures were dollar 1.07 lower than expected based on the changes observed in the control group. The average drug cost savings on all pharmacy claims were dollar 863 PPPM based on average prescription cost and dollar 873 PPPM based on PMPM analysis. The proportion of prescriptions for highcost drugs that were the target of the CDSS messages to prescribers was a relative 17.5% lower among the intervention group (35.8%) compared with the control group (43.4%; P=0.03). CONCLUSIONS: An electronic prescribing system with integrated decision support shifted prescribing behavior away from high-cost therapies and significantly lowered prescription drug costs. The savings associated with altered prescribing behavior offset the monthly subscription cost of the system. (+info)
Patient compliance with oral chemotherapy as assessed by a novel electronic technique.
(54/548)
PURPOSE: Previous reports have suggested low rates of compliance with the oral component of cancer chemotherapy, which, if confirmed, would have serious implications on treatment. Because of the uncertainties in the methodology used in previous studies, we have assessed compliance with a novel technique. PATIENTS AND METHODS: An "intelligent" tablet bottle was used, which, unknown to the patient, electronically records the times of opening over a period of weeks. The records were scored for overall compliance (total number of bottle openings as a percentage of the prescribed number) and for daily and hourly irregularity indices. Twenty-one patients undergoing treatment for Hodgkin's or non-Hodgkin's lymphoma were monitored for a total of 65 treatment periods, each of up to 2 weeks (852 days in total). Eight measures of side effects and quality of life were self-assessed daily by the patients using a diary card. RESULTS: The overall compliance was 100.6% +/- 20.6% (mean +/- SD). Overall compliance was lower (mean reduction, 10%) in treatment periods with drugs prescribed to be taken three times a day. It was not possible to demonstrate convincingly any relationship between compliance and any of the following: drug type, monitoring period sequence, the diary card scores of side effects and quality of life, number of relapses, and time since initial diagnosis. CONCLUSION: These results are reassuring, but further work is in progress to measure compliance in other treatment regimens in which the side effects are more severe and the prognosis is worse. (+info)
Stability and electronic spectra of C76N2 isomers.
(55/548)
Study of geometries of 16 possible isomers for C76N2 based on C78(C2v) by intermediate neglect of differential overlap (INDO) series of methods indicated that the most stable geometry 25,78-C76N2 where two nitrogen atoms substitute two apexes C25 and C78 near the shortest X axis and Y axis formed by two hexagons and a pentagon. Electronic structures and spectra of C76N2 were investigated. The reason for the red-shift for absorptions of C76N2 compared with that of C78(C2v) is discussed. (+info)
The role of psycho-social factors in headgear compliance.
(56/548)
The aim of this study was to identify the role of psycho-social factors in headgear compliance. Fifty-one patients, with an Angle Class II division 1 malocclusion comprised the study sample. The treatment plan aimed to correct the malocclusion using cervical pull headgear. An electronic module timer was attached to the neckstrap to evaluate the number of hours the patients wore the headgear. One of their parents was asked to answer the Child Behaviour Checklist (CBCL), which defines a patient's behaviour. The patients were monitored for 6 months and the modules were measured at the end of each 2 month period. Mann-Whitney U and Chi square tests were used to analyse the data. The patients were separated into groups according to their compliance. The results showed that although there were significant differences in the use of headgear between the groups (P < or = 0.001), age, gender, and CBCL subgroup scores were not statistically significant (P > 0.05). (+info)